DOCSLIB.ORG

Clinicalkey Drug Monographs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinicalkey Drug Monographs ClinicalKey Drug Monographs - Last Updated: 8 February 2018 Drug Name On CK A Thru Z 2013 A Thru Z Advantage 2013 A Thru Z Select 2013 Abacavir 09-05-2014 Abacavir; Lamivudine, 3TC 08-11-2013 Abacavir; Lamivudine, 3TC; Zidovudine, ZDV 08-11-2013 Abarelix 04-04-2014 Abatacept 2013 Abciximab 2013 Abetimus 2013 Abiraterone 30-01-2014 AbobotulinumtoxinA 2013 Absorbable Gelatin Sponge 2013 Acamprosate 2013 Acarbose 09-05-2014 Acebutolol 2013 Acerflex 2013 Acetaminophen 24-01-2014 Acetaminophen; Aspirin, ASA; Caffeine 2013 Acetaminophen; Brompheniramine; Dextromethorphan; Pseudoephedrine 2013 Acetaminophen; Brompheniramine; Pseudoephedrine 2013 Acetaminophen; Butalbital 24-01-2014 Acetaminophen; Butalbital; Caffeine 24-01-2014 Acetaminophen; Butalbital; Caffeine; Codeine 24-01-2014 Acetaminophen; Caffeine 2013 Acetaminophen; Caffeine; Chlorpheniramine; Hydrocodone; Phenylephrine 2013 Acetaminophen; Caffeine; Dihydrocodeine 24-01-2014 Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine 2013 Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide 24-01-2014 Acetaminophen; Chlorpheniramine 2013 Acetaminophen; Chlorpheniramine; Dextromethorphan 2013 Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine 2013 Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine 2013 Acetaminophen; Chlorpheniramine; Phenylephrine 2013 Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine 2013 Acetaminophen; Chlorpheniramine; Pseudoephedrine 2013 Acetaminophen; Clemastine; Pseudoephedrine 2013 Acetaminophen; Codeine 2013 Acetaminophen; Dexbrompheniramine; Pseudoephedrine 2013 Acetaminophen; Dextromethorphan 2013 Acetaminophen; Dextromethorphan; Doxylamine 2013 Acetaminophen; Dextromethorphan; Doxylamine; Pseudoephedrine 2013 Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine 2013 Acetaminophen; Dextromethorphan; Guaifenesin; Pseudoephedrine 2013 Acetaminophen; Dextromethorphan; Phenylephrine 2013 Acetaminophen; Dextromethorphan; Pseudoephedrine 2013 Acetaminophen; Dichloralphenazone; Isometheptene 2013 Acetaminophen; Diphenhydramine 2013 Acetaminophen; Diphenhydramine; Pseudoephedrine 2013 Acetaminophen; Guaifenesin; Phenylephrine 2013 Acetaminophen; Hydrocodone 14-02-2014 Acetaminophen; Melatonin 2013 Acetaminophen; Oxycodone 28-03-2014 Acetaminophen; Pamabrom 2013 Acetaminophen; Pamabrom; Pyrilamine 2013 Acetaminophen; Pentazocine 24-01-2014 Acetaminophen; Phenyltoloxamine 2013 Acetaminophen; Propoxyphene 2013 Acetaminophen; Pseudoephedrine 2013 Acetaminophen; Tramadol 24-01-2014 Acetazolamide 07-03-2014 Acetic Acid, Glacial 2013 Acetic Acid; Hydrocortisone 2013 Acetic Acid; Oxyquinoline; Ricinoleic Acid 2013 Acetohexamide 09-05-2014 Acetohydroxamic Acid 2013 Acetophenazine 2013 Acetylcholine Chloride 2013 Acetylcysteine 2013 Acidophilus with Pectin 2013 Acidulated Phosphate Fluoride 2013 Acitretin 2013 Acrivastine; Pseudoephedrine 2013 Acyclovir 14-04-2014 Acyclovir; Hydrocortisone 06-09-2013 Adalimumab 09-05-2014 Adapalene 2013 Adapalene; Benzoyl Peroxide 2013 Adefovir 2013 ADEKs 2013 ADEKs Drops 2013 Adenosine 27-11-2013 Adenovirus vaccine 2013 Ado-Trastuzumab emtansine 17-04-2014 Advanced NatalCare 2013 Advanced-RF NatalCare 2013 Advera 2013 Afatinib 17-04-2014 Aflibercept 2013 A-Free Prenatal 2013 Agalsidase Alfa 2013 Agalsidase Beta 2013 Airborne Effervescent Health Formula 2013 Airborne Jr. Effervescent Health Formula 2013 Airborne Sore Throat Gummi Lozenges 2013 Albendazole 10-01-2014 Albiglutide 09-05-2014 Albumin 2013 Albuterol 18-04-2014 Albuterol; Ipratropium 14-04-2014 Alcaftadine 2013 Alclometasone 2013 Aldesleukin, IL-2 26-12-2013 Alefacept 2013 Alemtuzumab 09-05-2014 Alendronate 2013 Alendronate; Cholecalciferol 2013 Alfentanil 2013 Alfimeprase 2013 Alfuzosin 05-05-2014 Alglucerase 2013 Alglucosidase alfa 2013 Alicaforsen 2013 Aliminase 2013 Aliskiren 08-11-2013 Aliskiren; Amlodipine 22-11-2013 Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ 08-11-2013 Aliskiren; Hydrochlorothiazide, HCTZ 08-11-2013 Aliskiren; Valsartan 09-05-2014 Alitretinoin 2013 Alkavite 2013 Allbee C-800 2013 AllBee Plus Vitamin C 2013 Allopurinol 2013 Almotriptan 2013 Aloe Polysaccharide; Iodoquinol 2013 Alogliptin 09-05-2014 Alogliptin; Metformin 22-11-2013 Alogliptin; Pioglitazone 09-05-2014 Alosetron 19-09-2013 Alpha lipoic acid 2013 Alpha-1-proteinase Inhibitor 2013 Alprazolam 28-03-2014 Alprostadil 04-10-2013 Alteplase, tPA 25-10-2013 Altretamine 2013 Aluminum Acetate, Burow's Solution 2013 Aluminum Chloride 2013 Aluminum Hydroxide 08-11-2013 Aluminum Hydroxide; Magnesium Carbonate 08-11-2013 Aluminum Hydroxide; Magnesium Hydroxide 08-11-2013 Aluminum Hydroxide; Magnesium Hydroxide; Simethicone 08-11-2013 Aluminum Hydroxide; Magnesium Trisilicate 08-11-2013 Alvimopan 2013 Amantadine 2013 Ambenonium Chloride 2013 Ambrisentan 19-09-2013 Amcinonide 2013 Amediplase 2013 Amifostine 2013 Amikacin 09-05-2013 Amiloride 09-05-2014 Amiloride; Hydrochlorothiazide, HCTZ 2013 Aminate Fe 2013 Aminobenzoate Potassium 2013 Aminocaproic Acid 2013 Aminoglutethimide 2013 Aminolevulinic Acid 2013 Aminosalicylate sodium, Aminosalicylic acid 05-05-2014 Aminosyn 10% 2013 Aminosyn 3.5% 2013 Aminosyn 3.5% M 2013 Aminosyn 5% 2013 Aminosyn 5% Sulfite-Free 2013 Aminosyn 7% 2013 Aminosyn 7% with Electrolytes 2013 Aminosyn 7% with Electrolytes Sulfite-Free 2013 Aminosyn 8.5% 2013 Aminosyn 8.5% Sulfite-Free 2013 Aminosyn 8.5% with Electrolytes Sulfite-Free 2013 Aminosyn II 10% Sulfite-Free 2013 Aminosyn II 10% with Electrolytes 2013 Aminosyn II 3.5% 2013 Aminosyn II 5% 2013 Aminosyn II 7% 2013 Aminosyn II 8.5% 2013 Aminosyn 10% Sulfite-Free 2013 Aminosyn 3.5% M Sulfite-Free 2013 Aminosyn 3.5% Sulfite-Free 2013 Aminosyn 7% Sulfite-Free 2013 Aminosyn 8.5% with Electrolytes 2013 Aminosyn -HBC 7% 2013 Aminosyn -HBC 7% Sulfite-Free 2013 Aminosyn II 2013 Aminosyn II 10% 2013 Aminosyn II 3.5% in Dextrose 25% 2013 Aminosyn II 8.5% Sulfite-Free 2013 Aminosyn -PF 10% 2013 Aminosyn -RF 5.2% 2013 Aminosyn-PF 7% Sulfite-Free 2013 Amiodarone 18-04-2014 Amiprilose 2013 Amitriptyline 28-03-2014 Amitriptyline; Chlordiazepoxide 11-10-2013 Amlexanox 2013 Amlodipine 19-09-2013 Amlodipine; Atorvastatin 06-12-2013 Amlodipine; Benazepril 22-11-2013 Amlodipine; Hydrochlorothiazide, HCTZ; Olmesartan 04-07-2013 Amlodipine; Hydrochlorothiazide, HCTZ; Valsartan 2013 Amlodipine; Olmesartan 04-07-2013 Amlodipine; Telmisartan 2013 Amlodipine; Valsartan 28-03-2014 Ammonium Chloride 2013 Ammonium Lactate 2013 Amobarbital 2013 Amoxapine 14-04-2014 Amoxicillin 2013 Amoxicillin; Clarithromycin; Lansoprazole 13-09-2013 Amoxicillin; Clavulanic Acid 21-08-2013 Amphetamine 2013 Amphetamine; Dextroamphetamine 07-03-2014 Amphotericin B 08-11-2013 Amphotericin B cholesteryl sulfate complex (ABCD) 2013 Amphotericin B lipid complex (ABLC) 2013 Amphotericin B liposomal (LAmB) 2013 Ampicillin 2013 Ampicillin; Sulbactam 13-03-2014 Amprenavir 19-09-2013 Amsacrine 2013 Amyl Nitrite 2013 Amylase; Cellulase; Lipase; Protease 2013 Anagrelide 04-04-2014 Anakinra 08-11-2013 Anastrozole 2013 Ancestim 2013 Ancrod 2013 Androstenedione 2013 Androvite 2013 Anemagen 2013 Anemagen OB 2013 Anemagen FA 2013 Anidulafungin 2013 Anisindione 2013 Anistreplase, APSAC 2013 Annamycin 2013 Antazoline; Naphazoline 2013 Anthralin 2013 Anthrax Vaccine, Adsorbed 2013 Anti-Gastrin Vaccine 2013 Antihemophilic Factor, AHF, Factor VIII 2013 Anti-inhibitor Coagulant Complex 03-01-2014 Antipyrine; Benzocaine 01-11-2013 Antipyrine; Benzocaine; Phenylephrine 2013 Antipyrine; Benzocaine; U-Polycosanol 410 2013 Antithrombin III 2013 Antithymocyte Globulin 2013 Apatate 2013 Apatate Forte 2013 Apixaban 09-05-2014 Apomorphine 04-04-2014 Apraclonidine 2013 Apremilast 04-04-2014 Aprepitant, Fosaprepitant 18-09-2013 Aprobarbital 2013 Aprotinin 2013 Ardeparin 19-06-2013 Arformoterol 14-04-2014 Argatroban 09-05-2014 Arginine 2013 Arimoclomol 2013 Aripiprazole 14-04-2014 Armodafinil 21-02-2014 Arsenic Trioxide 09-05-2014 Artemether 2013 Artemether; Lumefantrine 14-04-2014 Artesunate 2013 Articaine; Epinephrine 2013 Artificial Tears 2013 Ascocid -ISO-pH Vitamin C Powder 2013 Ascocid-500 D 2013 Ascocid-ISO-pH Vitamin C 2013 Ascorbic Acid, Vitamin C 04-06-2013 Asenapine 14-04-2014 Asoprisnil 2013 Asparaginase Erwinia chrysanthemi 28-03-2014 Aspirin, ASA 26-04-2013 Aspirin, ASA; Aluminum Hydroxide; Calcium Carbonate; Magnesium Hydroxide 2013 Aspirin, ASA; Butalbital; Caffeine 2013 Aspirin, ASA; Butalbital; Caffeine; Codeine 2013 Aspirin, ASA; Caffeine 2013 Aspirin, ASA; Caffeine; Dihydrocodeine 2013 Aspirin, ASA; Caffeine; Orphenadrine 2013 Aspirin, ASA; Caffeine; Propoxyphene 2013 Aspirin, ASA; Caffeine; Salicylamide 2013 Aspirin, ASA; Calcium Carbonate; Magnesium Oxide; Magnesium Carbonate 2013 Aspirin, ASA; Carisoprodol 2013 Aspirin, ASA; Carisoprodol; Codeine 2013 Aspirin, ASA; Citric Acid; Sodium Bicarbonate 2013 Aspirin, ASA; Codeine 2013 Aspirin, ASA; Diphenhydramine 2013 Aspirin, ASA; Dipyridamole 2013 Aspirin, ASA; Hydrocodone 2013 Aspirin, ASA; Meprobamate 2013 Aspirin, ASA; Methocarbamol 2013 Aspirin, ASA; Oxycodone 2013 Aspirin, ASA; Pentazocine 2013 Aspirin, ASA; Pravastatin 2013 Astemizole 04-04-2014 Astragalus, Astragalus membranaceus 2013 Atazanavir 14-04-2014 Atenolol 2013 Atenolol; Chlorthalidone 2013 Atomoxetine 19-12-2013 Atorvastatin 13-09-2013 Atorvastatin; Ezetimibe 20-05-2013 Atosiban 2013 Atovaquone 21-02-2014 Atovaquone; Proguanil 13-09-2013 Atracurium 2013 Atrasentan 2013 Atropine 01-05-2013 Atropine; Benzoic Acid; Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate 2013 Atropine; Difenoxin
Load more

Recommended publications
  • Novel Antagonists for the Human Adenosine
    UvA-DARE (Digital Academic Repository) Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6- trifluoromethylpurines and 1-deazapurines Koch, M. Publication date 2011 Document Version Final published version Link to publication Citation for published version (APA): Koch, M. (2011). Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6-trifluoromethylpurines and 1- deazapurines. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:05 Oct 2021 Novel antagonists for the human adenosine A Novel antagonists for the human adenosine Uitnodiging Novel antagonists for the voor het bijwonen van human adenosine de openbare verdediging van het proefschrift van A2A and A3 receptor via purine nitration Melle Koch op vrijdag 21 oktober 2011 om 14:00 uur in de Agnietenkapel van de Universiteit van Amsterdam Synthesis and biological evaluation Oudezijds Voorburgwal 231 of C2-substituted te Amsterdam 2A Na afloop van de promotie and A 6-trifluoromethylpurines zal hier tevens de receptie .
    [Show full text]
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • Practice Parameters for the Treatment of Patients with Dominantly Inherited Colorectal Cancer
    Practice Parameters For The Treatment Of Patients With Dominantly Inherited Colorectal Cancer Diseases of the Colon & Rectum 2003;46(8):1001-1012 Prepared by: The Standards Task Force The American Society of Colon and Rectal Surgeons James Church, MD; Clifford Simmang, MD; On Behalf of the Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons is dedicated to assuring high quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The standards committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created in order to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. Practice Parameters for the Treatment of Patients With Dominantly Inherited Colorectal Cancer Inherited colorectal cancer includes two main syndromes in which predisposition to the disease is based on a germline mutation that may be transmitted from parent to child.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert Et Al
    USOO6692728B2 (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert et al. (45) Date of Patent: Feb. 17, 2004 (54) POLYESTERS BASED ON HYDROXY FATTY (52) U.S. Cl. ......................... 424/59; 424/497; 424/489; ACDS AND LOWER HYDROXY ALKYL 424/70.11; 424/78.37; 424/78.08; 514/785; ACDS AND USES THEREOF 560/171; 560/172; 560/176; 560/183; 525/400 (58) Field of Search .......................... 424/59, 497, 489, (75) Inventors: Paul David Weipert, High Point, NC 424/70.11, 78.37; 514/785; 560/172,176, (US); Bharat B. Desai, Spartanburg, 183; 525/400 SC (US) (73) Assignee: Ethox Chemicals LLC, Greenville, SC ") References Cited (US) U.S. PATENT DOCUMENTS ( c: ) Notice: Subject to any disclaimer, the term of this 5,502,116 A 3/1996 Noda ......................... 525/415 patent is extended or adjusted under 35 5,614,576 A * 3/1997 Rutherford et al. ......... 524/270 U.S.C. 154(b) by 0 days. 5,851,937 A * 12/1998 Wu et al. ................... 442/394 * cited by examiner (21) Appl. No.: 10/388,426 (22) Filed: Mar 17, 2003 Primary Examiner Sabiha Qazi 9 (74) Attorney, Agent, or Firm-Isaac A. Angres (65) Prior Publication Data (57) ABSTRACT US 2003/0175222 A1 Sep. 18, 2003 The present invention provides biodegradable polyesters Related U.S. Application Data based on lower hydroxy acids and hydroxy fatty acids. The resulting polyesters are useful as cosmetic vehicles for (62) Division of application No. 09/805,894, filed on Mar. 15, Sunscreens, skin lotions and by themselves are also useful as 2001, now Pat.
    [Show full text]
  • Ontario Drug Benefit Formulary Edition 43
    Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care Effective February 28, 2018 Visit Formulary Downloads: Edition 43 Table of Contents Part I Introduction ....................................................................................................... I.1 Part II Preamble .......................................................................................................... II.1 Part III-A Benefits List ........................................................................................... III-A.1 Part III-B Off-Formulary Interchangeable Drugs (OFI) ........................................ III-B.1 Part IV Section Currently Not In Use ......................................................................... IV Part V Index of Pharmacologic-Therapeutic Classification .................................... V.1 Part VI-A Facilitated Access - HIV/AIDS .............................................................. VI-A.1 Part VI-B Facilitated Access - Palliative Care ..................................................... VI-B.1 Part VI-C Temporary Facilitated Access - Rheumatology ................................. VI-C.1 Part VII Trillium Drug Program ................................................................................ VII.1 Part VIII Exceptional Access Program (EAP) ........................................................ VIII.1 Part IX-A Nutrition Products ................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Annexes to the EMA Annual Report 2009
    Annual report 2009 Annexes The main body of this annual report is available on the website of the European Medicines Agency (EMA) at: http://www.ema.europa.eu/htms/general/direct/ar.htm 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. Contents Annex 1 Members of the Management Board..................................................... 3 Annex 2 Members of the Committee for Medicinal Products for Human Use .......... 5 Annex 3 Members of the Committee for Medicinal Products for Veterinary Use ....... 8 Annex 4 Members of the Committee on Orphan Medicinal Products .................... 10 Annex 5 Members of the Committee on Herbal Medicinal Products ..................... 12 Annex 6 Members of the Paediatric Committee................................................ 14 Annex 7 National competent authority partners ............................................... 16 Annex 8 Budget summaries 2008–2009 ......................................................... 27 Annex 9 European Medicines Agency Establishment Plan .................................. 28 Annex 10 CHMP opinions in 2009 on medicinal products for human use .............. 29 Annex 11 CVMP opinions in 2009 on medicinal products for veterinary use.......... 53 Annex 12 COMP opinions in 2009 on designation of orphan medicinal products
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]
  • Medical Policy Statement
    MEDICAL POLICY STATEMENT Effective Next Annual Last Review / Date Review Date Revision Date 06/15/2011 06/15/2012 06/15/2011 Author Shelley Jones RN, CCM, Wendy Null RPh CSMG Medical Policy Statements are derived from literature based and supported clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services are those health care services or supplies which are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative and are not provided mainly for the convenience of the member or provider. A. SUBJECT Alglucerase (Ceredase) Infusion B. BACKGROUND Alglucerase (Ceredase) is a modified form of the enzyme, ß-glucocerebrosidase (ß-D- glucosyl-N-acylsphingosine glucohydrolase). Alglucerase (Ceredase) catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. Glucocerebroside is primarily derived from hematologic cell turnover. Gaucher disease is characterized by a functional deficiency in ß-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages, which become engorged and are termed Gaucher cells. The patient selection criteria outlined was derived from the FDA-approved prescribing information for alglucerase (Ceredase), the studies that were presented to the FDA in support of the pre-market approval application, and studies in the peer-reviewed published medical literature.
    [Show full text]